Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients

BACKGROUND: Bevacizumab improves outcome for most recurrent glioblastoma patients, but the duration of benefit is limited and survival after initial bevacizumab progression is poor. We evaluated bevacizumab continuation beyond initial progression among recurrent glioblastoma patients as it is a comm...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Reardon, D A, Herndon, J E, Peters, K B, Desjardins, A, Coan, A, Lou, E, Sumrall, A L, Turner, S, Lipp, E S, Sathornsumetee, S, Rich, J N, Sampson, J H, Friedman, A H, Boulton, S T, Bigner, D D, Friedman, H S, Vredenburgh, J J
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2012
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3493761/
https://ncbi.nlm.nih.gov/pubmed/23037712
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2012.415
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados